...
首页> 外文期刊>Molecular cell >Point Mutations in v-Myb Disrupt a Cyclophilin-Catalyzed negative Regulatory Mechanism
【24h】

Point Mutations in v-Myb Disrupt a Cyclophilin-Catalyzed negative Regulatory Mechanism

机译:v-Myb中的点突变破坏了亲环蛋白催化的负调控机制。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

The c-Myb protein is controlled by intramolecular interactions, and point mutations can enhance its oncogenic activity. We tested whether conformational changes regulate c-Myb and found that Cyp-40, a widely distributed cyclophilin and peptidyl-prolyl isomerase, could inhibit c-Myb DNA binding activity. Inhibition by Cyp-40 required both its C-terminal protein-interaction domain, which bound specifically to c-Myb, and its N-terminal catalytic domain and was blocked by the competitive inhibitor cyclosporin A. Cyp-40 failed to bind or inhibit the oncogenic derivative v-Myb, which has a mutated Cyp-40 binding site. These results suggest that mutations in v-Myb allow it to evade a negative regulatory mechanism mediated by enzymes such as Cyp-40, and implicate peptidyl-prolyl isomerases in the regulation of transcription, transformation, and differentiation.
机译:c-Myb蛋白受分子内相互作用的控制,点突变可增强其致癌活性。我们测试了构象变化是否调节c-Myb,发现Cyp-40,一种广泛分布的亲环蛋白和肽基-脯氨酰异构酶,可以抑制c-Myb DNA结合活性。 Cyp-40的抑制作用既需要其C末端蛋白相互作用域(与c-Myb特异性结合),又需要其N末端催化域,并且被竞争性抑制剂环孢菌素A阻断。Cyp-40不能结合或抑制Cyp-40。致癌衍生物v-Myb,具有突变的Cyp-40结合位点。这些结果表明,v-Myb中的突变使其能够逃避酶(例如Cyp-40)介导的负调控机制,并在转录,转化和分化的调控中牵涉肽基-脯氨酰异构酶。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号